Smart biomaterials for smarter healthcare.

As the world seeks answers to the growing threat of antibiotic resistance, Smart Healing solutions represent a new standard in patient care. Evolving at the intersection of technology and human biology, our technologies reduce antibiotic treatments and enable a better quality of life for patients.

It’s time to heal smarter.

For patient wellbeing

To enable a faster recovery time, fewer surgeries and a higher quality of life for patients, Smart Healing solutions are comprised of natural biological compounds for use in both adult and pediatric patients.

For professionals

Our solutions aim to minimize the complexity and amount of procedures that medical professionals perform, increasing the capacity of hospital organizations and their personnel to provide better care for more patients.

For global healthcare

Smart Healing enables procedures that are more cost-effective and less invasive and bring several other benefits. By aiming to help solve a global problem through improved patient care, Bonalive is committed to creating a better future for the healthcare ecosystem.

Bioactive technology

At the core of our technology is S53P4 bioactive glass – a smart biomaterial consisting solely of elements that exist naturally in the human body.

Characterized by its ability to firmly attach to living tissue and chemically bond with surrounding bone, S53P4 bioactive glass naturally facilitates the formation of new bone. Thus, it is a unique material for filling defects and replacing damaged bone tissue because S53P4 bioactive glass functions as naturally as your biology.

Smart Healing solutions are osteostimulative* and come with a range of benefits for filling, reconstructing and regenerating bone defects as well as for filling bone cavities, voids and gaps in both adult and pediatric patients.

*non-osteoinductive

News

Publication

Chronic osteomyelitis and infected non-union treatment

May 24, 2018 09:48

A new publication has been published on the use of Bonalive bioactive glass in Infected Non-Unions and Chronic Osteomyelitis treatment. Infection with a single pathogen was demonstrated in 50% of...

Publication

Cost-effectiveness of Bonalive® granules

March 28, 2018 09:51

A recent congress paper at the ORS 2018 Annual Meeting compares the cost-effectiveness of a one-stage treatment of chronic osteomyelitis using Bonalive® granules with a two-stage treatment using gentamicin loaded...

Bonalive is EBJIS 2018 Gold Sponsor

March 28, 2018 09:50

We are thrilled to welcome you to the 37th annual meeting of the EBJIS hosted in the capital of Finland, home country of BonAlive. BonAlive will be the Gold Sponsor...

Publication

Bonalive® in mastoidal infections surgery

December 19, 2017 10:01

A new doctoral thesis on BonAlive® bioactive glass S53P4 in chronic middle ear treatment and mastoidal infections surgery has been published. According to the study, bioactive glass (BG S53P4) is...